- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Trial initiation date, PD(L)-1 Biomarker, IO biomarker: AcS (clinicaltrials.gov) - May 8, 2017 P2, N=300, Not yet recruiting, N=18 --> 11 Initiation date: Feb 2017 --> Jun 2017
- |||||||||| Journal: Heterogeneous Appearance of Central Nervous System Involvement in Malignant Mixed Müllerian Tumors. (Pubmed Central) - May 6, 2017
As illustrated by the heterogeneous clinicopathologic features of our two cases as well as the reviewed literature, CNS metastasis of MMMTs is diagnostically challenging, shows a variable outcome, and thus requires individualized treatment. In the present cases and CNS metastases reported to date, a higher histologic ratio of sarcomatous to epithelial components portends a worse outcome.
- |||||||||| Journal: Diseases of the tongue. (Pubmed Central) - May 5, 2017
The oral cavity, along with the tongue, are sites of neoplasms, reactive processes, and infections, and may be a harbinger of systemic diseases. This review includes both common and rare diseases that occur on the tongue, including: vascular and lymphatic lesions (infantile hemangiomas and oral varices), reactive and inflammatory processes (hairy tongue, pigmented fungiform papillae of the tongue, benign migratory glossitis, and fissured tongue), infections (oral hairy leukoplakia, herpes simplex and varicella-zoster virus infections, human papillomavirus, and candidiasis), premalignant lesions (leukoplakia and erythroplakia), malignant lesions (squamous cell carcinoma, Kaposi sarcoma, and lymphoproliferative diseases), and signs of systemic disease (nutritional deficiency and systemic amyloidosis).
- |||||||||| Recentin (cediranib) / AstraZeneca
Trial primary completion date, Monotherapy, Metastases: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - May 4, 2017 P2, N=70, Recruiting, This review includes both common and rare diseases that occur on the tongue, including: vascular and lymphatic lesions (infantile hemangiomas and oral varices), reactive and inflammatory processes (hairy tongue, pigmented fungiform papillae of the tongue, benign migratory glossitis, and fissured tongue), infections (oral hairy leukoplakia, herpes simplex and varicella-zoster virus infections, human papillomavirus, and candidiasis), premalignant lesions (leukoplakia and erythroplakia), malignant lesions (squamous cell carcinoma, Kaposi sarcoma, and lymphoproliferative diseases), and signs of systemic disease (nutritional deficiency and systemic amyloidosis). Trial primary completion date: Apr 2017 --> Apr 2018
- |||||||||| trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 4, 2017 P2, N=35, Completed, Trial primary completion date: Jan 2017 --> Jan 2018 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
- |||||||||| Journal: Endometrial adenosarcoma in the setting of a germline DICER1 mutation: A case report. (Pubmed Central) - May 3, 2017
Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016 •DICER1 mutations play a significant role in gynecologic malignancy.•DICER1 may be involved in the sarcomagenesis of endometrial adenosarcoma.•The knowledge of a genetic mutation can help clarify a patient's medical history.
- |||||||||| imatinib / Generic mfg.
Trial completion: Study to Evaluate Imatinib in Desmoid Tumors (clinicaltrials.gov) - May 3, 2017 P2, N=39, Completed, •DICER1 mutations play a significant role in gynecologic malignancy.•DICER1 may be involved in the sarcomagenesis of endometrial adenosarcoma.•The knowledge of a genetic mutation can help clarify a patient's medical history. Active, not recruiting --> Completed
- |||||||||| Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Monotherapy, Pan tumor: Trial of Afatinib in Pediatric Tumours (clinicaltrials.gov) - May 3, 2017 P1, N=60, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Feb 2019
- |||||||||| Enrollment closed: A Study of Lymphoseek (clinicaltrials.gov) - May 3, 2017
P2, N=27, Active, not recruiting, N=92 --> 200 | Trial primary completion date: Jun 2017 --> Aug 2019 | N=92 --> 200 | Trial primary completion date: Jun 2017 --> Aug 2019 Recruiting --> Active, not recruiting
- |||||||||| Yondelis (trabectedin) / PharmaMar, J&J, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, IO biomarker, Metastases: SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - May 3, 2017 P1/2, N=45, Active, not recruiting,
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS
Biomarker, Review, Journal: Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. (Pubmed Central) - Apr 28, 2017 In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
- |||||||||| Recentin (cediranib) / AstraZeneca
Trial completion, Trial primary completion date, Combination therapy: Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Apr 28, 2017 P1/2, N=46, Completed, We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study. Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Apr 2014
- |||||||||| Enrollment change, Trial primary completion date, Metastases: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Apr 28, 2017
P2, N=78, Active, not recruiting, N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 N=36 --> 78 | Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| cabazitaxel / Generic mfg.
Enrollment open, Trial primary completion date, Metastases: cabazL06470: Ph II Cabazitaxel DD Liposarcoma (clinicaltrials.gov) - Apr 28, 2017 P2, N=100, Recruiting, N=36 --> 78 | Trial primary completion date: Dec 2016 --> Dec 2017 Suspended --> Recruiting | Trial primary completion date: Feb 2017 --> Feb 2019
- |||||||||| Tecelra (afamitresgene autoleucel) / Adaptimmune
New P1 trial, Pan tumor: MAGE-A4? (clinicaltrials.gov) - Apr 27, 2017 P1, N=32, Not yet recruiting,
|